



**PARTICIPANT STATISTICS**

**FIRST QUADRIMESTER 2017**

**VIRAL ANTIGEN SCREEN, Waived**

Influenza Type A Method	Specimen 1			Specimen 2		
	Neg	Pos	Pos for A or B	Neg	Pos	Pos for A or B
Alere	3				3	
Alere i	4				4	
BD Veritor	43	3		1	45	
Binax NOW Flu A&B, wv	71	2		1	72	
Henry Schein One Step +	4				4	
Quidel Quick Vue Infl A+B	42	1		1	41	1
Quidel Sofia	6				6	
Sekisui OSOM A&B	9				9	
<b>Total Population</b>	<b>185</b>	<b>6</b>	<b>0</b>	<b>3</b>	<b>187</b>	<b>1</b>
<b>Flagging</b>		***	***	***		

Influenza Type B Method	Specimen 1		Specimen 2	
	Neg	Pos	Neg	Pos
Alere I	4		4	
Alere	3		3	
BD Veritor	46		46	
Binax NOW Flu A&B, wv	72		71	
Henry Schein One Step +	4		4	
Quidel Quick Vue Infl A+B	41	1	41	1
Quidel Sofia	6		6	
Sekisui OSOM A&B	9		8	1
<b>Total Population</b>	<b>188</b>	<b>1</b>	<b>186</b>	<b>2</b>
<b>Flagging</b>		***		***

Respiratory Syncytial Virus Method	Specimen 1		Specimen 2	
	Neg	Pos	Neg	Pos
Alere Binax Now		12	11	1
Quidel QuickVue	1	12	12	1
Quidel Sofia		3	3	
<b>Total Population</b>	<b>1</b>	<b>30</b>	<b>29</b>	<b>2</b>
<b>Flagging</b>	***			***

Adenovirus Method	Specimen 1		Specimen 2	
	Neg	Pos	Neg	Pos
<b>Total Population</b>	<b>0</b>	<b>6</b>	<b>6</b>	<b>0</b>
<b>Flagging</b>	***			***

Correct responses are defined as those reflecting agreement among 80% or more of all participants or referees. Unacceptable responses are indicated by "\*\*\*\*\*" on the Flagging line of each specimen.